pubmed.ncbi.nlm.nih.gov

L-Leucine and NO-mediated cardiovascular function - PubMed

Review

L-Leucine and NO-mediated cardiovascular function

Ying Yang et al. Amino Acids. 2015 Mar.

Abstract

Reduced availability of nitric oxide (NO) in the vasculature is a major factor contributing to the impaired action of insulin on blood flow and, therefore, insulin resistance in obese and diabetic subjects. Available evidence shows that vascular insulin resistance plays an important role in the pathogenesis of cardiovascular disease, the leading cause of death in developed nations. Interestingly, increased concentrations of L-leucine in the plasma occur in obese humans and other animals with vascular dysfunction. Among branched-chain amino acids, L-leucine is unique in inhibiting NO synthesis from L-arginine in endothelial cells and may modulate cardiovascular homeostasis in insulin resistance. Results of recent studies indicate that L-leucine is an activator of glutamine:fructose-6-phosphate aminotransferase (GFAT), which is the first and a rate-controlling enzyme in the synthesis of glucosamine (an inhibitor of endothelial NO synthesis). Through stimulating the mammalian target of rapamycin signaling pathway and thus protein synthesis, L-leucine may enhance GFAT protein expression, thereby inhibiting NO synthesis in endothelial cells. We propose that reducing circulating levels of L-leucine or endothelial GFAT activity may provide a potentially novel strategy for preventing and/or treating cardiovascular disease in obese and diabetic subjects. Such means may include dietary supplementation with either α-ketoglutarate to enhance the catabolism of L-leucine in the small intestine and other tissues or with N-ethyl-L-glutamine to inhibit GFAT activity in endothelial cells. Preventing leucine-induced activation of GFAT by nutritional supplements or pharmaceutical drugs may contribute to improved cardiovascular function by enhancing vascular NO synthesis.

PubMed Disclaimer

Cited by

Interplay Between Plasma Glycine and Branched-Chain Amino Acids Contributes to the Development of Hypertension and Coronary Heart Disease.
Dziedzic M, Józefczuk E, Guzik TJ, Siedlinski M. Dziedzic M, et al. Hypertension. 2024 Jun;81(6):1320-1331. doi: 10.1161/HYPERTENSIONAHA.123.22649. Epub 2024 Apr 8. Hypertension. 2024. PMID: 38587181 Free PMC article.
Plasma Branched-Chain and Aromatic Amino Acids in Relation to Hypertension.
Mahbub MH, Yamaguchi N, Hase R, Takahashi H, Ishimaru Y, Watanabe R, Saito H, Shimokawa J, Yamamoto H, Kikuchi S, Tanabe T. Mahbub MH, et al. Nutrients. 2020 Dec 10;12(12):3791. doi: 10.3390/nu12123791. Nutrients. 2020. PMID: 33322015 Free PMC article.
Evidence of Nitric Oxide Impairment During Hypertensive Pregnancies.
Dela Justina V, Dos Passos Júnior RR, Lima VV, Giachini FR. Dela Justina V, et al. Adv Exp Med Biol. 2023;1428:99-125. doi: 10.1007/978-3-031-32554-0_5. Adv Exp Med Biol. 2023. PMID: 37466771 Review.
Gallic Acid-L-Leucine Conjugate Protects Mice against LPS-Induced Inflammation and Sepsis via Correcting Proinflammatory Lipid Mediator Profiles and Oxidative Stress.
Cheng Y, Li X, Tse HF, Rong J. Cheng Y, et al. Oxid Med Cell Longev. 2018 Mar 25;2018:1081287. doi: 10.1155/2018/1081287. eCollection 2018. Oxid Med Cell Longev. 2018. PMID: 29765489 Free PMC article.
Understanding the Causes and Implications of Endothelial Metabolic Variation in Cardiovascular Disease through Genome-Scale Metabolic Modeling.
McGarrity S, Halldórsson H, Palsson S, Johansson PI, Rolfsson Ó. McGarrity S, et al. Front Cardiovasc Med. 2016 Apr 18;3:10. doi: 10.3389/fcvm.2016.00010. eCollection 2016. Front Cardiovasc Med. 2016. PMID: 27148541 Free PMC article. Review.

L-Leucine and NO-mediated cardiovascular function - PubMed